Evidence map›Paper›PMID 38798564›Full record

ArticleResearch square2024

The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion.

Xin Hu, Bo Zhu, Natalie Vokes, Junya Fujimoto, Frank R Rojas Alvarez, Simon Heeke, Andre L Moreira, Luisa M Solis, Cara Haymaker, Vamsidhar Velcheti and 29 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Xin HuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Bo ZhuDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Natalie VokesDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-3766-5335
Junya FujimotoHiroshima University Hospital, Hiroshima 7348551, Japan.
Frank R Rojas AlvarezDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Simon HeekeDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-5916-534X
Andre L MoreiraDepartment of Pathology, New York University Langone Medical Center, New York, 10012, USA.
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-1253-630X
Cara HaymakerDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-1317-9287
Vamsidhar VelchetiDepartment of Medical oncology, New York University, New York, 10012, USA.
Daniel H StermanDepartment of Pulmonary, New York University, New York, 10012, USA.ORCID 0009-0004-0170-2722
Harvey I PassDepartment of Cardiothoracic Surgery, New York University Langone Medical Center, New York, 10016, USA.
Chao ChengDepartment of Medicine, Epidemiology and Population Science, Baylor College of Medicine. Houston, TX, 77030, USA.ORCID 0000-0002-5002-3417
Jack J LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-5469-9214
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-5412-9860
Zhubo WeiDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jia WuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-8392-8338
Xiuning LeDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-8554-1185
Edwin OstrinDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-4538-6539
Iakovos ToumazisDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Don GibbonsDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-2362-3094
Dan SuInstitute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China.ORCID 0000-0002-8423-1994
Junya FukuokaDepartment of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 8528523, Japan.
Mara B AntonoffDepartment of Thoracic & Cardiovasc Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-6247-9537
David E GerberHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0002-7812-6741
Chenyang LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-8109-9388
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-2976-9115
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-9380-0266
Mark DavisMoores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.ORCID 0000-0001-6868-657X
John V HeymachDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-9068-8942
Samir HannashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-4210-1593
Ignacio WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Steven DubinettDepartments of Medicine and Pathology, University of California Los Angeles and Greater Los Angeles Healthcare System, Los Angeles, CA, 90095, USA.ORCID 0000-0003-3656-8039
Ludmil AlexandrovMoores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.
Scott LippmanMoores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.
Avrum SpiraPathology & Laboratory Medicine, and Bioinformatics, Boston University, Boston, MA, 02215, USA.
Andrew P FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-8663-2671
Alexandre ReubenDepartments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-4510-0382
Jianjun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-7872-3477

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHANG, JIANJUN · 2019 to 2023
$1.8M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA234629NIH HHS S10 OD024977
6 · The paper itself

Abstract

Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular features underlying LUAD precancer evolution. We observed progressively increasing mutations, chromosomal aberrations, whole genome doubling and genomic instability from precancer to invasive LUAD, indicating aggravating chromosomal instability (CIN). Telomere shortening, a crucial genomic alteration linked to CIN, emerged at precancer stage. Moreover, later-stage lesions demonstrated increasing cancer stemness and decreasing alveolar identity, suggesting epithelial de-differentiation during early LUAD carcinogenesis. The innate immune cells progressively diminished from precancer to invasive LUAD, concomitant with a gradual recruitment of adaptive immune cells (except CD8

Indexed as

alveolar differentiationcancer evolutionchromosomal instabilityimmune evasionlung adenocarcinomapre-cancerstemness

Identifiers

PMID38798564
PMCPMC11118701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.